Exelixis (EXEL) Net Cash Flow Growth (3y) (2013 - 2026)
Exelixis (EXEL) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Exelixis | 14.44 Bn | 13.66 Bn | 590.86 Mn | -104.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -104.13% |
| Jan 2, 2026 | 37.68% |
| Oct 3, 2025 | 75.67% |
| Jul 4, 2025 | 42.11% |
| Apr 4, 2025 | -34.96% |
| Jan 3, 2025 | -37.97% |
| Sep 27, 2024 | 0.39% |
| Jun 28, 2024 | -35.93% |
| Mar 29, 2024 | -26.72% |
| Dec 29, 2023 | -45.33% |
| Mar 31, 2023 | -24.30% |
| Sep 30, 2022 | 32.12% |
| Jul 1, 2022 | -188.49% |
| Apr 1, 2022 | 7.45% |
| Dec 31, 2021 | 54.14% |
| Oct 1, 2021 | -17.45% |
| Jul 2, 2021 | 96.74% |
| Apr 2, 2021 | 29.15% |
| Jan 1, 2021 | 53.96% |
| Apr 3, 2020 | 42.35% |